Skip to content

TransMedics

US · TMDX #2536 by market cap Listed 2019
85.25 -8.77 -9.33%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Recent news

  • Rating change
    CCORF Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $124
    Market Newswire · 2026/6/30
  • Rating change
    Needham Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $106
    Market Newswire · 2026/9/22
  • Rating change
    Needham Maintains TransMedics(TMDX.US) With Buy Rating, Cuts Target Price to $106
    Market Newswire · 2026/8/3
  • Rating change
    A Quick Look at Today's Ratings for TransMedics(TMDX.US), With a Forecast Between $95 to $106
    Market Newswire · 2026/9/11
  • Rating change
    Evercore Maintains TransMedics(TMDX.US) With Buy Rating, Cuts Target Price to $90
    Market Newswire · 2026/7/6
  • Rating change
    A Quick Look at Today's Ratings for TransMedics(TMDX.US), With a Forecast Between $95 to $122
    Market Newswire · 2026/8/5
  • Rating change
    Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Cuts Target Price to $120
    Market Newswire · 2026/7/7
  • Barclays Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $120
    Market Newswire · 2026/11/9
  • Rating change
    TransMedics (TMDX): Buy Rating Backed by Accelerating U.S. Organ Transplant Volumes and Expanding OCS Utilization
    TipRanks · 2026/8/3
  • Rating change
    William Blair Maintains TransMedics(TMDX.US) With Buy Rating
    Market Newswire · 2026/10/2
  • Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $100
    Market Newswire · 2026/11/6
  • A Quick Look at Today's Ratings for TransMedics(TMDX.US), With a Forecast Between $70 to $120
    Market Newswire · 2026/11/7
  • Rating change
    Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Raises Target Price to $100
    Market Newswire · 2026/9/12
  • Rating change
    CCORF Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $95
    Market Newswire · 2026/8/13
  • Rating change
    Oppenheimer Maintains TransMedics(TMDX.US) With Hold Rating
    Market Newswire · 2026/8/24
  • CCORF Maintains TransMedics(TMDX.US) With Buy Rating, Cuts Target Price to $94
    Market Newswire · 2026/10/13
  • Rating change
    Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $120
    Market Newswire · 2026/7/22
  • TD Cowen Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $120
    Market Newswire · 2026/11/3
  • Rating change
    Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Cuts Target Price to $90
    Market Newswire · 2026/9/2
  • Rating change
    Barclays Initiates TransMedics(TMDX.US) With Buy Rating, Announces Target Price $120
    Market Newswire · 2026/10/7
  • Rating change
    Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), Aquestive Therapeutics (AQST) and Alto Neuroscience, Inc. (ANRO)
    TipRanks · 2026/6/26
  • Rating change
    Stifel Maintains TransMedics(TMDX.US) With Hold Rating, Maintains Target Price $80
    Market Newswire · 2026/6/26
  • TD Cowen Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $120
    Market Newswire · 2026/10/2
  • Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $100
    Market Newswire · 2026/10/5
  • GUIDANCE: (TMDX) TransMedics Expects Full Year 2026 Revenue Range $737M - $757M, Vs. FactSet Est of $743.1M
    MT Newswires · 2026/9/11

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:02:23 · For reference only, not investment advice and not tailored to your situation.

TransMedics discussion 0 comments

Add a comment